top of page

Double Duty: Early Research Reveals how a Single Drug Delivers Twice the Impact in Fragile X

  • lindsayvicars
  • Jun 27, 2022
  • 1 min read

From the University of Rochester Medical Center Newsroom:


Like many neurological diseases, there’s a lot we don’t understand about fragile X syndrome. But, after studying the disorder for several years, Lynne Maquat’s lab knew two important things: the enzyme AKT, which plays a key role in cell growth and survival, and the quality control pathway known as NMD (nonsense-mediated mRNA decay), are both in overdrive in fragile X.

 

In a new study in the journal Molecular Cell, the team reveals how these two major players interact, highlighting a complex molecular dance that could inform the development of future treatments for fragile X syndrome. (click here to keep reading)


Author: Emily Boynton

Комментарии


Join our mailing list for updates on CERRT training opportunities and events!

Email us at 
nyrnacoe@albany.edu

Thanks for joining the CERRT mailing list!

CERRT RNA Research

CERRT @ The RNA Institute 1400 Washington Ave.

Albany, NY 12222

  • LinkedIn

518-591-8814

© 2025 by The RNA Institute. Powered and secured by Wix

bottom of page